explore -WSS

explore

author：focus 2025-10-01 20:14:40 - browse：961

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： What we owe ALS patients — and why one company fell short

WSS

The biotech scorecard for Q4: 16 stock

RSV injection headlines need to be accurate for good uptake

6 solutions to address cancer drug shortages and others

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

What will Novo Nordisk's VC do with its influx of cash?

Study points to new risk in gene therapy death of Terry Horgan

hotspot

explore

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The United States is paying nearly triple for new Covid vaccines

Medical leaders decry Supreme Court decision on affirmative action

Will an HIV vaccine ever be a reality?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Alabama frozen embryo ruling has major implications for IVF clinics

New air purifier tech could be key to improving indoor air quality

RSV injection headlines need to be accurate for good uptake

Sports medicine is finally prioritizing gender equality

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

entertainment

Some top drug companies are starting to take action on climate

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

He's a Nobel laureate. Critics say he was misleading on Covid

In utero gene editing: an explainer

Congress extends some pandemic preparedness programs

Why palliative psychiatry is worth discussing

Wikipedia

entertainment

hotspot

focus